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Under clinical development since the early 90’s and with two successfully approved
drugs (Fomivirsen and Mipomersen), oligonucleotide-based therapeutics has not yet
delivered a clinical drug to the market in the cancer field. Whilst many pre-clinical data
has been generated, a lack of understanding still exists on how to efficiently tackle
all the different challenges presented for cancer targeting in a clinical setting. Namely,
effective drug vectorization, careful choice of target gene or synergistic multi-gene
targeting are surely decisive, while caution must be exerted to avoid potential toxic,
often misleading off-target-effects. Here a brief overview will be given on the nucleic
acid chemistry advances that established oligonucleotide technologies as a promising
therapeutic alternative and ongoing cancer related clinical trials. Special attention will be
given toward a perspective on the hurdles encountered specifically in the cancer field by
this class of therapeutic oligonucleotides and a view on possible avenues for success is
presented, with particular focus on the contribution from nanotechnology to the field.
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OPENING THE THERAPEUTIC LANDSCAPE BY EVOLUTION
OF NUCLEIC ACIDS CHEMISTRY
Oligonucleotides have been under investigation for over 30
years, whilst achieving only two approved drugs. Those were,
Fomivirsen, approved by the FDA in 1998 for the treatment of
cytomegalovirus retinitis in patients with AIDS, but discontin-
ued for low demand, and Mipomersen, FDA approved in 2013,
targeting ApoB100 for the treatment of homozygous familial
hypercholesterolaemia (HoFH), a rare genetic disorder that leads
to excessive levels of low-density lipoprotein (LDL) cholesterol.
These are both single-stranded antisense oligonucleotide drugs
(most commonly known as AONs) that together with siRNA (a
double-stranded oligonucleotide) make up, at present, the thera-
peutic antisense oligonucleotide field. In this paper more empha-
sis will be put on AONs due to their longer time in development
and history of clinical trials.
Progress in this field has been proceeding at a steady but some-
what slow pace, driven mostly by the speed at which the different
intra and extracellular obstacles encountered by the oligonu-
cleotide drugs are being tackled. Themost important hurdles have
been (i) the poor stability against extra- and intracellular degra-
dation (mostly by action of nucleases), (ii) inefficient intracellular
delivery to target cells or tissues, (iii) inadequate affinity toward
the intended target sequence and (iv) potential off-target/toxicity
effects. Finally for most applications (v) immunostimulation has
also been a matter of concern.
The pursuit of clinically relevant antisense drugs has led the
field to develop different types of chemical modifications to native
DNA or RNA in an attempt to overcome the aforementioned
limitations. Most widely used modifications can be divided in
two simple categories: (a) backbone structure and (b) sugar ring
modifications (Table 1).
The main goals of these chemical modifications have been to
achieve increased resistance to degradation by exo- and endo-
nucleases; increase affinity, and in some cases selectivity, toward
target RNA/DNA sequences and to modulate the immunostimu-
lation properties of the oligonucleotides.
In the case of phosphorothioate (PS) modification (one of
the first and widely used modifications introduced in therapeu-
tic antisense oligonucleotides) (Eckstein, 1967), it has also led to
better pharmacokinetics and extended circulation times for AONs
systemically applied in a “naked” form (i.e., unprotected by deliv-
ery agents). This effect has been attributed to unspecific binding
to serum proteins such as albumin (Srinivasan et al., 1995; Crooke
et al., 1996; Watanabe et al., 2006).
Mechanistically, AONs work via binding to a specific RNA tar-
get sequence resulting in the block of RNA function. This can
be achieved through steric hindrance (non-degradative pathway)
and concomitant RNA translation block, or target degradation.
The latter occurs by the action of an endogenous enzyme, RNase
H, or alternatively, by a catalytic cleavage activity embedded
into the oligonucleotide itself (e.g., ribozymes and DNAzymes)
(Bennett and Swayze, 2010). Notably, the non-degradative mech-
anism, through steric hindrance, has recently been exploited,
with great success, for modulation of pre-mRNA splice patterns
by affecting the binding of trans-splicing regulatory factors to
the pre-mRNA (Hammond and Wood, 2011; Bestas et al., 2014;
Disterer et al., 2014).
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Table 1 | Common nucleic acids modifications divided by category.
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The mechanism of action of AONs has to be carefully con-
sidered when deciding for the type of nucleotide modifica-
tions and design of the oligonucleotide (here including number
and position of modified nucleotides). Thus, in contrast to PS
modifications that maintain the anionic character of oligonu-
cleotides, PNAs and PMOs completely substitute the phosphodi-
ester linkage by either a polyamide backbone (Nielsen et al., 1991)
or a phosphorodiamidate group (Summerton and Weller, 1997),
respectively, hence being uncharged nucleotide analogs. On the
other hand sugar ring modifications can influence the nucleoside
conformation promoting the preferential adoption of an A-form
(dsRNA type) or B-form (dsDNA type) helix when in a double-
stranded structure. In the case of 2′O-Me RNA (Kawai et al.,
1992; Nishizaki et al., 1997), MOE (Manoharan, 1999) and LNA
(Koshkin et al., 1998; Obika et al., 1998), all promote the A-form
while 2′F-ANA (Berger et al., 1998) the B-form. Contrasting all
the aforementioned, UNA, with its unlocked ring configuration,
does not impart any conformation restrictions (Pasternak and
Wengel, 2011).
All of the abovementioned nucleotide modifications have
thus been used with few restrictions when designing steric hin-
drance AONs, since their incorporation mainly focus on achiev-
ing enhanced binding affinity and selectivity toward a target
sequence. In contrast, the design of AONs for target degrada-
tion through the action of RNAse H has to obey the enzyme’s
structural preferences for cleaving DNA/RNA duplexes (Minshull
and Hunt, 1986; Nakamura et al., 1991). Hence, all modifica-
tions too divergent from natural DNA nucleotides need to be
carefully considered to not hinder the enzyme action. This can
be accomplished by the design of “gapmer” AONs containing
the modified nucleotides on the 5′ and 3′ terminus flanking a
central unmodified DNA nucleotides stretch (Monia et al., 1993;
Stanton et al., 2012). Specifically, in the case of the two approved
drugs, Fomivirsen is a PS modified DNA oligonucleotide applied
by intraocular injection, whereas Mipomersen is a second gener-
ation AON gapmer with MOE modifications at the ends and PS
throughout, applied as an intravascular injection.
BRIEF OVERVIEW ON ANTISENSE OLIGONUCLEOTIDES
CLINICAL TRIALS RELATED TO CANCER
An increasing number of clinical trials with AONs are ongoing,
which shows that the field is rapidly forwarding. In Table 2 a list
of recently completed and on-going clinical trials is presented.
Other studies have unfortunately failed, in different phases,
to reach their expected endpoints or to show significant benefit,
leading to a stop in the corresponding AON development. Some
aspects of antisense technology have contributed to this and are
next discussed.
CHALLENGES FOR ANTISENSE TECHNOLOGY—1.
UNSPECIFIC MODES OF ACTION
Along their development path, oligonucleotides have unraveled
much of their potential but also many of their limitations.
As discussed above, introduction of PS modifications led to
the first evidences that antisense drugs could become a reality in a
clinical setting, essentially by increasing resistance to degradation
and extending circulation times after systemic administration
(mostly due to unspecific serum-protein binding). These prop-
erties improved the oligonucleotide therapeutic potential, despite
some decreased affinity for the target sequence (when comparing
to regular DNA oligonucleotides) (Kibler-Herzog et al., 1991). On
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Table 2 | On-going and recently completed anti-cancer AON clinical trials.
DRUG AON (carrier) TARGET INDICATION STATUS DEVELOPER
Custirsen (OGX-011) 2′-O-MOE-PS gapmer ODN
(“naked”)
Clusterin (i) castrate resistant prostate
cancer; (ii) non-small cell lung
cancer
I and (ii) Phase III
(recruiting)
OncoGenex
EGFR antisense
DNA
Phoshorothioate ODN
(“naked”)
EGFR Advanced Head and Neck
Squamous Cell Carcinoma
Phase I/II (recruiting) University of Texas
Apatorsen (OGX-427) 2′-O-MOE-PS gapmer ODN
(“naked”)
Hsp27 prostate cancer; pancreatic;
non-squamous non-small cell
lung cancer; other
Phase II (recruiting) OncoGenex
ISIS-STAT3Rx (ISIS
481464/ AZD9150)
cEt-PS gapmer ODN
(“naked”)
STAT3 Lymphoma; hepatocellular
carcinoma
Phase I/II (recruiting) Astrazeneca
(ISIS Pharmaceuticals)
ISIS-ARRx
(AZD5312)
cEt-PS gapmer ODN
(“naked”)
Androgen
Receptor
Advanced solid tumors
(prostate cancer indications)
Phase I (recruiting) Astrazeneca
(ISIS Pharmaceuticals)
Trabedersen (AP
12009)
Phoshorothioate ODN
(“naked”)
TGFβ2 (i) Pancreatic Neoplasms,
Melanoma, Colorectal
Neoplasms; (ii) Glioblastoma;
Anaplastic Astrocytoma
(i) Phase I; (ii) Phase
IIb (both completed)
Isarna Therapeutics
EZN-2968 LNA-PS gapmer ODN
(“naked”)
HIF-1α Advanced solid tumors Phase I (completed) Enzon Pharmaceuticals
(Santaris Pharma)
LErafAON-ETU DNA-PS modified at 5′ and 3′ end
(lipossome)
c-raf Advanced Cancer Phase I
(completed)
INSYS Therapeutics Inc
ODN—oligodeoxynucleotide; cEt—constrained Ethyl.
the other hand, this unspecific protein binding feature can poten-
tially lead to associated toxicities or cellular effects not entirely
sequence specific, such as complement activation, increased coag-
ulation times and unwanted immune activation (Brown et al.,
1994; Krieg and Stein, 1995; Henry et al., 1999; Mou et al., 2001;
Krieg et al., 2003; Senn et al., 2005). These effects, however, are
most often oligonucleotide length and concentration dependent
(Webb et al., 2001). Immune activation, on the other hand, is
also enhanced by specific nucleotide sequences (CpG motifs)
(Barchet et al., 2008), although this can be minimized by dif-
ferent types of nucleotide modifications (Henry et al., 2000).
Nevertheless, immune activation is an important factor that has
previously led to erroneous interpretations of data when inhibi-
tion of tumor growth was not primarily driven by the antisense
mechanism but by the immunostimulatory properties of CpG
sequences found in certain AONs (Badros et al., 2005; Gekeler
et al., 2006). Regarding potential PS-derived unspecific cellular
effects these have been proposed to affect themechanism of action
of an anti-cancer oligonucleotide drug by the down-regulation
of several anti-apoptotic proteins and glycolytic enzymes. These
were actually seen as important contributors to the apoptotic
action (Stessl et al., 2009; Winkler et al., 2010).
Another important concern relates to hybridization depen-
dent toxicity, deriving from exaggerated pharmacological action
(a consequence also seen with any other chemical drug), or off-
target hybridization. The latter can be minimized by designing
the antisense drug taking into account a detailed bioinformatics
analysis for identification of both, genes with perfect matches or
with partial complementarity (looking out for 1–3 mismatches as
the most relevant ones) (Bennett and Swayze, 2010).
The above considerations have raised some difficulties, espe-
cially in vivo, for the exact prediction of the mechanism of action
of an antisense drug and are among the causes probably hamper-
ing a more resolute demonstration of the therapeutic relevance
of antisense drugs toward not only cancer but also other diseases
in general. This concern can be demonstrated by the case of the
antisense drug LY2275796 (a second generation AONwith PS and
MOE modifications targeting eIF-4E) where, besides target gene
downregulation, housekeeping genes were considerably affected
as well, raising the question to whether the antisense action was
sequence specific or also mediated by off-target effects (Hong
et al., 2011).
This scenario only reinforces the need for an in-depth phar-
macologic and pharmacokinetic analysis at the preclinical stage
of AON development.
CHALLENGES FOR ANTISENSE TECHNOLOGY—2. DELIVERY
The efficient and targeted delivery of nucleic acid therapeutics
is seen as, if not the biggest, one of the most important chal-
lenges for this class of drugs. The most commonly used nucleic
acids drugs (namely, plasmid DNA, siRNA and AONs) have spe-
cific features influencing their cellular uptake and delivery vector
development. AONs, due to the short chain size have very low
charge density, in addition, being single-stranded, they have the
www.frontiersin.org October 2014 | Volume 2 | Article 87 | 3
Moreno and Pêgo AON cancer therapeutics
aromatic bases exposed (not buried inside a double helix), which
confers a slight hydrophobic character to the molecule. These
properties, enable some level of interaction with the cell mem-
brane, which can be further potentiated by PS modifications,
making possible, although still extremely inefficient, their use
without the help of any vector formulations (Watts and Corey,
2012). This has been recently emphasized by the demonstra-
tion that short LNA modified AONs were able to sustain gene
downregulation in a large variety of cell lines when adminis-
tered in vitro unassisted by transfection agents (also referred as
gymnotic delivery), although some cell lines still seem to be
completely refractory to this type of AON uptake (Stein et al.,
2010). The results obtained by gymnotic delivery seem to cor-
relate well with the obtained in vivo gene silencing efficiencies
for the “naked” LNA administration; in fact, a better prediction
of in vivo potency was obtained in comparison to data resulting
from transfection-mediated in vitro AON delivery, a more stan-
dard method to preliminarily analyze AON efficiency (Stein et al.,
2010). A similar study showed downregulation of different cancer
gene targets, by the gymnotic delivery of LNA-AON in over 30 cell
lines, although discrepancies between both studies are seen when
relating intracellular localization of the AONs (nuclear vs. cyto-
plasmatic) and efficient down-regulation activity (Zhang et al.,
2011).
Despite several studies demonstrating some activity when
using “naked” AONs in vivo, and their wide tissue distribution, it
has also been realized that these preferentially accumulate in the
liver and kidney and to a lesser extent in spleen, lymph nodes and
bone marrow (Agrawal et al., 1995; Iversen et al., 1995; Graham
et al., 1998; Geary, 2009; Straarup et al., 2010). Liver, as a pri-
mary location of oligonucleotide accumulation has received a
greater level of attention with some of the most promising AON
trials taking advantage of this effect, as seen with Mipomersen
(Hovingh et al., 2013). Liver accumulation has been attributed to
the role of this organ in clearance by the reticulum endothelium
system (RES). This results from the abundant presence of phago-
cytic Kupffer cells, together with the high blood flow received
and, importantly, the existence of a fenestrated vasculature with
an average 100–200 nm pore diameter between endothelial lining
cells (Wisse et al., 2008). It should be noted that the pharma-
cokinetics of AONs are dependent on chemistry, with the most
favorable properties relating to the presence of PS linkages and
the polyanionic character of the molecules. Thus, AONs based
on PNA and PMO when administered as “naked” formulations
in vivo, are rapidly cleared from circulation while showing poorer
tissue distribution (Dirin and Winkler, 2013).
Tumor tissue also shares some of the abovementioned fea-
tures, specially regarding its specific microvasculature character-
istics (viz. for solid tumors). Fenestrations of 100–700 nm have
been found in some tumor vessels, which together with a poor
lymphatic drainage give rise to the enhanced permeability and
retention effect (EPR) (Jang et al., 2003), responsible for the accu-
mulation of macromolecules or nanoparticles in tumors. Another
effect to consider is the usually high interstitial fluid pressure
(IFP) in tumors that obviates the normal rapid convective flow
from blood to the tissue interstitium (due to osmotic and hydro-
static pressure differences). This effect is counterproductive in
terms of drug accessibility to the tumor tissue, which then has
to rely in slow diffusion processes. A dense structure of intersti-
tial matrix and cells also mounts a final barrier to the diffusion
process (Chauhan et al., 2011). Finally, the uneven leakiness of
vessels found in tumors further contributes to a highly heteroge-
neous process of drug penetration. Another consideration is that
the larger the tumor the bigger the regional differences within the
tumor itself. This is illustrated by the presence of a necrotic core
with an almost complete absence of blood flow, a seminecrotic
region with poor blood flow within un-branched vessels, a stable
region with branched vessels and good flow and an active angio-
genic front where blood flow is variable and can be substantially
higher than in surrounding host normal tissues (Jain, 2012).
These hindrances can result in AONs despite reaching tumor
tissue, not being able to accumulate to a significant extent in
the tumor tissue, with the additional drawback of distributing
unevenly throughout the tissue (Plenat et al., 1995; Delong et al.,
1997; Devi et al., 2005).
Certainly these delivery issues hamper a more effective trans-
lation of anti-cancer antisense oligonucleotides to the clinic.
PERSPECTIVES ON AON VECTORIZATION FOR CANCER
THERAPEUTICS
Given the wide tissue distribution properties of AONs and their
preferential accumulation in organs other than tumor tissue, this
can lead to the necessity of using high amounts of AONs in order
to reach a meaningful biological effect, raising concerns due to
presence of high AON concentrations in unspecific tissue/organs.
In addition, although some level of localization to tumor tissue is
attained due to the EPR effect, there can be a large heterogene-
ity in the targeting and distribution of AONs between tumors
and within the same tumor. Not achieving a homogeneous and
abundant distribution of AONs to the entire tumor can result
in differential intracellular concentrations of the AON affecting
functional efficiency and ultimately leading to some cells evading
the anti-cancer action.
The development of nanocarriers for AON delivery could have
a positive contribution in AON anti-cancer efficiency while mini-
mizing toxicity, although their utility must be evaluated in a case-
by-case basis. Nanoparticle systems will be also affected by inter
and intra-tumor heterogeneity, where differences between tumor
mass strongly influence the EPR and IFP effects. In fact, the EPR
effect is more prevalent in tumors of 100mm3 which limits its
use when targeting small or unvascularized primary or secondary
tumor (metastases) (Adiseshaiah et al., 2010). While AONs asso-
ciated with nanoparticle systems can take greater advantage of
the EPR effect, when “naked” administration is employed these
will be affected to a wider extent by IFP similarly to small drugs
Interestingly, this could mean that free AONs could have an
advantage when dealing with a tumor with a less disturbed vascu-
lar architecture or when tumor vasculature normalization drugs
are used (Juliano et al., 2009; Chauhan et al., 2012). This view can,
however, be too simplistic as shown in a work dealing with imag-
ing and modulation of AON microdistribution in solid tumor
xenografts (Mocanu et al., 2007). It was seen that a drug-induced
decrease in IFP was not accompanied by an expected improved
distribution of the AON, in contrast to what has been reported
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for some small drugs. This was attributed to a strong association
of the AON with regions of necrosis/hypoxia or due to the effect
of the drug promoting neovascularization and the less permeable
status of the newly formed vessels. Also, one could reason that the
tumormatrix and the specific collagen content along with the sta-
tus of other fibrilliary proteins could affect distribution of AONs
(Netti et al., 2000; Mocanu et al., 2007), especially when dealing
with PS-AONs due to their unspecific binding properties. In con-
trast to tumor normalization, the EPR effect can be transiently
augmented by modulation of blood pressure and local increase of
blood flow through the use of angiotensin-II-induced hyperten-
sion and nitric oxide releasing agents (Fang et al., 2011). In this
way uptake of nanoparticle systems could be favored.
In terms of available systems for vectorization of AONs these
can be divided in nanoparticle systems formed by interactions
of different carrier formulations with the AONs or nanoconju-
gates where AONs are covalently linked to different functional
molecules (e.g., peptides, sugars) (Juliano et al., 2012; Yin et al.,
2014).
Carrier formulations that have been frequently used for
delivery of different nucleic acids comprise cationic lipids and
polymers. The basic driving force of complex formation is the
electrostatic interaction. In brief, the carrier system needs to
(i) protect the nucleic-acid from extracellular and intracellular
degradation, until it reaches its target, (ii) achieve a prolonged
circulation time in order to be accumulated in the location of
interest, (iii) efficiently interact with the cellular membrane to
promote uptake (generally through endocytosis processes), (iv)
promote escape from endocytic vesicles and finally (v) dissociate
from the active nucleic-acid in order for it to function (Yin et al.,
2014).
Cationic lipids generally used with nucleic acids (forming
lipoplexes) comprise DOTMA, DOSPE, DOTAP, but also neu-
tral lipids such as the fusogenic DOPE have been incorpo-
rated to improve transfection efficiency (Simoes et al., 2005).
Some of these lipids have been studied specifically with AONs
(Jaaskelainen et al., 2000; Meidan et al., 2001; Gokhale et al.,
2002) but few have been utilized in pre-clinical or clinical work.
A liposome formulation of c-raf antisense oligonucleotide con-
stitutes the first example of an AON-lipoplex taken into clinical
development stages (Zhang et al., 2009).
Polymers have been also used. These have an immense chemi-
cal diversity and are easy to chemically manipulate thus enabling
tuning of properties by functionalization. Some examples of poly-
meric systems that have been utilized are poly(L-Lysine) (Stewart
et al., 1996) and poly(ethylene imine) (Seong et al., 2006).
However, some issues regarding efficiency and toxicity have war-
ranted the development of other systems based on natural and
biodegradable polymers such as chitosan (Gomes et al., 2014).
Also worth mentioning are delivery systems based on inor-
ganic nanoparticles, an emerging field, of which, gold nanopar-
ticles are perhaps the most representative ones (Ding et al., 2014).
A detailed view on the intracellular transport (e.g., understanding
its endocytic route) (Wu et al., 2014) and careful evaluation of
toxicity profile (e.g., genotoxicity, membrane damage) (Alkilany
and Murphy, 2010) can provide important information to the
advancement of the technology into clinical development.
Taking into consideration the previously mentioned tumor
features, some design specificities should be taken into account
when implementing an AON-nanocomplex strategy as anti-
cancer therapeutic platform. Regarding size, the smaller the parti-
cle the better the intra-tumoral transport (<10 nm), however the
EPR effect will be less significant than for bigger particles (10–
200 nm) (Netti et al., 2000). On the other hand, particles on the
higher size range will present a limited capacity to extravasate
from vessel pores, but for the same reason will be more spe-
cific. Also, bigger sizes determine a higher clearance by the RES,
although this can be counteracted by steric stabilization through
poly(ethylene glycol) surface modification (Van Vlerken et al.,
2007).
Surface charge also plays a crucial role. While cationic par-
ticles tend to target tumor endothelium and exhibit a higher
vascular permeability than neutral or anionic ones, the fastest
and more homogenously distribution in tumor interstitium is
seen for the neutral particles. Presence of charge in particles con-
tributes to aggregation with different components of the tumor
matrix thus hindering transport. Accordingly, neutral or zwit-
terionic particles, or even particles with the property to change
charge according to the microenvironment should perhaps be the
best options (Chauhan et al., 2011). Shape, an often-overlooked
property, likewise affects transport. Here factors such as rigid-
ity and form (spherical vs. rod) come into play with flexible
nanometer-sized particles showing, in principle, better transport
characteristics (Chauhan et al., 2011).
In conclusion, the field of anti-cancer AONs is rapidly advanc-
ing, supported in part by the growing number of chemical mod-
ifications that conferred superior properties to AONs. However,
specific and efficient delivery to tumors is still of uttermost
importance. Uniform distribution throughout the tumor is an
important challenge particularly due to intra-tumoral regional
specificities and a progressive microenvironment. A further chal-
lenge lies in the dynamic nature of tumors that may correlate with
temporal and spatial changes in expression of the AON target
genes.
Multi-gene targeting AONs and efficient tumor targeting vec-
torization systems will, thus, be of uttermost importance in the
development of a successful anti-cancer AON strategy.
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